High cholesterol — what to add, what to avoid
For mildly elevated LDL without other ASCVD risk factors, the supplement layer can produce 10–25% LDL reductions when stacked correctly — comparable to a low-dose statin. For high-risk patients, that's not enough and statins are the right answer. The most-evidenced supplement levers are soluble fiber, plant sterols, and (for triglycerides) marine omega-3. Bergamot is a promising newer entrant; red yeast rice is the supplement landmine.
The supplement layer with credible evidence
Psyllium husk (soluble fiber)
7–10 g/day in divided doses with water, taken before meals
Psyllium and other soluble fibers bind bile acids in the gut, forcing hepatic conversion of cholesterol into new bile acids, which lowers serum LDL. Meta-analyses show 7 g/day produces roughly 6–9 mg/dL LDL reductions; higher doses produce somewhat more. FDA-permitted health claim covers psyllium and oat beta-glucan for cardiovascular risk reduction. Start at 5 g/day and titrate up to 10 g/day in divided doses to manage GI side effects (bloating, gas). Take separately from medications (4-hour gap) to avoid absorption interactions.
Plant sterols / stanols
2 g/day with fat-containing meals
Plant sterols (and the saturated forms, stanols) compete with cholesterol for absorption in the small intestine via NPC1L1 — the same target as ezetimibe. 2 g/day reduces LDL by 8–10%; higher doses do not produce proportionally more effect. Available as soft-gels, fortified spreads, and supplements. Must be taken with fat-containing meals for absorption. Combine well with statins (additive ~6% LDL reduction).
Bergamot (Citrus bergamia)
500–1,000 mg/day standardised polyphenolic fraction (BPF)
Bergamot polyphenols (BPF, standardised to ~38% polyphenols) have produced 15–25% LDL reductions and 10–15% triglyceride reductions in multiple RCTs at 500–1,000 mg/day for 12 weeks. The mechanism includes HMG-CoA reductase modulation (similar pathway to statins, distinct from interaction concern) and improved LDL receptor expression. Effect is modest but additive to statins in some trials. The newer "Bergamonte"-branded extract is the most-studied. Reasonable adjunct or first-line supplement for users with mild dyslipidemia who refuse or cannot tolerate statins.
Marine omega-3 (EPA/DHA)
2–4 g EPA+DHA/day for triglyceride reduction
For elevated triglycerides (especially >200 mg/dL), high-dose EPA+DHA reduces TGs by 20–30%. The REDUCE-IT trial of prescription icosapent ethyl (purified EPA, 4 g/day) showed cardiovascular event reduction in statin-treated high-risk patients with elevated TGs. OTC fish oil at 1 g/day has shown no event-reduction benefit in primary prevention (VITAL, ASCEND). LDL may rise slightly with high-dose omega-3 — this is expected and not adverse.
Oat beta-glucan
3 g/day soluble fiber from oats or supplement
Oat beta-glucan (the soluble fiber in oats) has the same bile-acid-binding mechanism as psyllium. 3 g/day reduces LDL by ~7%. Achievable through dietary oats (1 cup cooked oatmeal ≈ 2 g beta-glucan) or supplement. FDA-permitted health claim.
The niacin question — useful but inconvenient
Niacin (nicotinic acid, not nicotinamide) at 1,500–3,000 mg/day is the only supplement that meaningfully raises HDL (15–35%) and is the most potent triglyceride-lowering nutraceutical (20–50% reductions). However, the AIM-HIGH and HPS2-THRIVE trials showed niacin added to statin therapy did not reduce cardiovascular events and increased adverse events. Plain niacin at therapeutic doses causes flushing in most users; "no-flush" niacin (inositol hexanicotinate) does not deliver the lipid effects. Sustained-release niacin has hepatotoxicity signal. For most users, the trial outcome data make niacin a marginal recommendation.
What to skip
- Red yeast rice — contains monacolin K, which is chemically identical to lovastatin. Some products have meaningful "statin" content; others have negligible amounts; consistency is poor. In 2022 the EU restricted red yeast rice products to under 3 mg monacolin K per daily dose. The "natural alternative to statins" framing obscures that the active ingredient IS a statin, with the same myopathy and rhabdomyolysis risk and the same drug interactions, but without dosing standardization or prescriber oversight.
- Garlic for LDL — older trials suggested an effect; better recent meta-analyses suggest the LDL effect is small to negligible. Useful for BP (see hawthorn vs garlic comparison) but not the right tool for LDL.
- Policosanol — early Cuban trials showed dramatic effects; independent replication in non-Cuban populations has been disappointing. Likely a "lab-of-origin" effect.
- Resveratrol — does not meaningfully reduce LDL or triglycerides in human trials despite "heart healthy red wine" framing.
- "Cholesterol control" multi-ingredient complexes — typically include subtherapeutic doses of plant sterols + red yeast rice + niacin + bergamot; pay for individual ingredients at trial-tested doses instead.
The non-supplement layer that matters more
Cardiovascular risk is overwhelmingly driven by smoking status, blood pressure, glycemia, and LDL — and the largest LDL lever is a statin if you're at risk. Mediterranean-style diet, replacing saturated with unsaturated fats, weight loss in the overweight, aerobic exercise, and smoking cessation produce real LDL and CV outcome improvements. Supplement stacks deliver useful 10–25% LDL reductions; statins deliver 30–55% LDL reductions plus event-reduction evidence.